CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025
Rhea-AI Summary
CorMedix (Nasdaq: CRMD), a biopharmaceutical company developing therapeutic products for life-threatening diseases, has scheduled its first quarter 2025 financial results announcement for May 6, 2025, before market opening.
The company will host a corporate update conference call at 8:30am Eastern Time on the same day. Interested parties can join through:
- Domestic call-in: 1-844-676-2922
- International call-in: 1-412-634-6840
- Conference ID: 10198548
- Webcast available via provided link
Positive
- Timely financial reporting compliance with scheduled Q1 2025 results announcement
- Management's proactive investor communication through scheduled conference call
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, CRMD gained 0.66%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BERKELEY HEIGHTS, N.J., April 29, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the first quarter ended March 31, 2025, before the market opens on Tuesday, May 6, 2025, and will host a corporate update conference call at 8:30am Eastern Time.
| Tuesday, May 6th @ 8:30am ET | |
| Domestic: | 1-844-676-2922 |
| International: | 1-412-634-6840 |
| Conference ID: | 10198548 |
| Webcast: | Webcast Link |
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix is commencing clinical studies in Total Parenteral Nutrition and Pediatric patient populations in 2025 and also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) release Q1 2025 financial results?
How can investors join the CorMedix (CRMD) Q1 2025 earnings call?
What time is the CorMedix (CRMD) Q1 2025 earnings conference call?
What will CorMedix (CRMD) discuss in their May 6 conference call?
What is the international dial-in number for CRMD's Q1 2025 earnings call?
